Actively Recruiting
Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
Led by Peking Union Medical College Hospital · Updated on 2025-12-17
40
Participants Needed
1
Research Sites
81 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to evaluate the diagnostic performance of Al18F-NOTA-LM3 PET/CT and compare it with 68Ga-DOTATATE PET/CT in patients with pheochromocytoma/paraganglioma (PPGL).
CONDITIONS
Official Title
Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 80 years
- Suspected or confirmed pheochromocytoma or paraganglioma (PPGL) patients
You will not qualify if you...
- Presence of other types of tumors
- Severe liver dysfunction (ALT/AST 65 times upper limit of normal)
- Severe renal dysfunction (glomerular filtration rate less than 30 ml/min)
- Pregnant or breastfeeding women
- Inability to undergo PET/CT scans
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
H
Hongli Jing
CONTACT
Y
Yuwei Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here